Abstract: Provided are methods of treating rheumatoid arthritis by inhibiting Neuromedin U signalling.

Abstract: Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7.

Abstract: Methods and compositions for treating obesity and related disorders. The methods include the use of Sca-1+ progenitor cells treated with BMP-2, -4, -5, -6, and/or -7.

Abstract: Provided are methods and compositions that enhance Nrf2 (SKN-1) activation of phase II detoxification or antioxidant enzyme transcription, comprising plant extracts (e.g., willow extracts) or active fractions thereof, as well as methods for identifying additional compounds that increase the Nrf2-regulation of those enzymes.

Abstract: Methods of preventing, delaying, or reducing the development or severity of obesity-associated disorders, including administering Fat-specific regulatory T cells, or administering factors secreted by said T cells.

Abstract: This invention relates to methods for the treatment of atherosclerotic cardiovascular disease using a non-acetylated forms of salicylate, e.g., salsalate and/or trilisate.

Abstract: Described herein are methods for identifying and using inhibitors of Necdin function to promote brown adipose tissue (BAT) differentiation, thereby treating obesity.

Abstract: Described are non-invasive methods for imaging pancreatic inflammation in living mammals using Magnetic Nanoparticle Probes (MNPs).

Abstract: Described are methods of identifying modulators of metabolic memory, for the treatment of microvascular complications of diabetes, as well as methods of use thereof. Also described are methods of treating microvascular complications of diabetes by decreasing expression and/or activity of SHP-1.

Abstract: Methods and compositions for treating obesity and related disorders. The methods include the use of stem cells treated with BMP-2, -4, -5, -6 and/or -7.

Abstract: The present inventors discovered that PKC? is necessary for VEGF signaling through PI3K/Akt-dependent pathways and is involved in MAPK-dependent pathways, thus regulating eNOS activity and DNA synthesis, respectively. Thus differential manipulation of PKC? activity can be used to modify VEGF effects in conditions in which modulation of angiogenesis is desirable (e.g., for treatment of diabetic proliferative retinopathy or to enhance angiogenesis for treatment of peripheral and myocardial ischemia).

Abstract: The present invention provides methods for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema.

Abstract: The invention provides methods of screening for compounds that increase levels or activity of Aryl hydrocarbon Nuclear Receptor Translocator (ARNT) and/or Hypoxia Inducible Factor 1? (HIF1?), for the treatment and prevention of diabetes-related disorders, including type 1 and type 2 diabetes mellitus, impaired glucose tolerance, insulin resistance and beta cell dysfunction; compounds identified by said screening methods; and methods of using said compounds. Also included are methods for treating or preventing diabetes-related diseases using ARNT and/or HIF1? polypeptides and polynucleotides, and for using information regarding the expression, level or activity of ARNT and/or HIF1? in predictive medicine, e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics.

Abstract: The invention provides isolated mMafA polypeptides, nucleic acids, vectors and host cells containing them, which encode a novel insulin related transcription factor. Diagnostic methods, methods of selecting and differentiating insulin-producing cells, and methods of treatment utilizing compositions of the invention are also provided.

Abstract: Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment.

Abstract: This invention relates to methods for reducing chronic subacute inflammatory states associated with obesity and improve glycemia, thereby preventing or delaying the development of type 2 diabetes (T2D) in obese subjects, or subjects with the metabolic syndrome, using non-acetylated forms of salicylate, e.g., salsalate or trilisate.

Abstract: Methods are disclosed for diagnosing increased risk of cardiovascular disease in a subject.

Abstract: Described are methods for predicting and diagnosing genetically-based obesity and body fat distribution, and for identifying compounds for the treatment and prevention of obesity.

Abstract: This invention relates to methods and compositions for enhancing hematopoietic stem cell mobilization by inhibiting early growth response-1 (egr1) activity.

Abstract: Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7.